单纯良性前列腺增生与合并慢性前列腺炎患者临床特点分析

目的:探讨单纯良性前列腺增生(BPH)与合并慢性前列腺炎(CP)患者的临床特点及其意义。方法:回顾性分析2011年10月~2013年06月我院泌尿外科行经尿道前列腺等离子电切术(TURP)治疗BPH的患者236例,按照病理诊断分为单纯BPH(35例)和合并CP(201例)两组,采用SPSS 17.0软件进行统计学分析,比较两组患者在年龄、前列腺体积、最大尿流率(Qmax)、剩余尿量(RUV)、国际前列腺症状评分(IPSS)(术前及术后3个月)、生活质量评分(QOL)、是否发生急性尿潴留(AUR)、前列腺特异性抗原(PSA)、前列腺特异性抗原密度(PSAD)等指标上是否存在差异。结果:合并CP组患者在前列腺体积、RUV、IPSS、QOL、AUR发生率等方面指标高于单纯BPH组患者,Qmax低于单纯BPH组,差异有统计学意义。而在年龄及PSA、PSAD等方面指标差异无统计学意义。手术治疗后3个月两组IPSS评分均较术前明显降低,且合并CP组较单纯组评分高,差异均有统计学意义。结论:CP可能是BPH临床进展的重要因素之一,同时也可能是导致BPH患者下尿路症状(LUTS)的重要原因之一。

Clinical analysis of BPH and BPH with chronic prostatitis

Objective： To analyze the clinical characteristics and significance of simple benign prostatic hyper- plasia （BPH） and BPH with chronic prostatitis （CP）. Method.. From October 2011 to June 2013, 236 patients who underwent transurethral resection of the prostate were enrolled in this study. They were divided into BPH group （ n =35） and BPH with CP group （ n =201） according to the pathological diagnosis. We used SPSS 17.0 software for statistical analysis to compare the two groups in age, volume of prostate, maximum urinary flow rate （ Q max）, residual urine volume （RUV）, preoperative and postoperative three months＇ International Prostate Symp- tom Score （IPSS）, quality of life （QOL） score, the incidence of acute urinary retention （AUR）, prostate specific antigen （PSA）, prostate specific antigen density （PSAD）. Thus, we could determine whether there were differ- ences among them. Result.. Volume of prostate, RUV, IPSS, QOL and the risk of AUR of the patients in BPH with CP group were significantly higher than BPH group, while Q max was lower than BPH group. The data showed statistical differences. Nevertheless, the indexes of age, PSA and PSAD weren＇t found statistical signifi- cance. Three months after surgery IPSS of both groups decreased significantly compared with preoperative condi- tion, and the score of BPH with CP group was higher than BPH group, which the differences were statistically significant. Conclusion： CP may be a key factor in the clinical progression of BPH and one of the important reasons leading to lower urinary tract symptoms （LUTS） in patients with BPH.